New NK cell treatments for lymphoma patients who didn't respond to CAR-T therapy.
Next Generation Engineered NK Cells for Lymphoma Patients after CD19 CAR-T Cell Failure.
This study is looking at new ways to use natural killer (NK) cells to help patients with certain blood cancers who haven't had success with previous CAR-T cell treatments, aiming to create a safer and more effective option for them.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-11041192 on NIH RePORTER |
What this research studies
This research focuses on developing next-generation natural killer (NK) cell therapies for patients with B-cell lymphoid malignancies who have relapsed after receiving CD19 CAR-T cell therapy. The approach involves enhancing the effectiveness and longevity of NK cells through advanced techniques such as costimulatory signaling and checkpoint inhibition. By targeting specific tumor antigens, this research aims to provide a safer and more effective treatment option for patients who have limited choices after CAR-T therapy failure.
Who could benefit from this research
Good fit: Ideal candidates for this research are lymphoma patients who have experienced a relapse after CD19 CAR-T cell therapy.
Not a fit: Patients who have not undergone CAR-T therapy or those with other types of malignancies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could offer a new, effective treatment option for lymphoma patients who have not responded to existing therapies.
How similar studies have performed: Previous studies have shown promising results with similar NK cell therapies, indicating potential for success in this novel approach.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Daher, May — University of Tx Md Anderson Can Ctr
- Study coordinator: Daher, May
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.